Table 1.
Echocardiographic analysis of Med1cKO mice
| Genotype | n | Sex | HR, Beats/min | EDV, μl | ESV, μl | Mass, mg | SV, μl | CO, μl/m | EF, % |
|---|---|---|---|---|---|---|---|---|---|
| Postnatal | |||||||||
| Med1fl/fl | 11 | M | 672 ± 22 | 13.8 ± 0.94 | 2.6 ± 0.26 | 42.2 ± 4.3 | 11.3 ± 0.7 | 7437 ± 657 | 82.0 ± 0.01 |
| Med1cKO | 8 | M | 449 ± 24* | 47.8 ± 14.3* | 32.4 ± 13.4* | 66.2 ± 11.4* | 15.3 ± 1.7** | 6639 ± 513 | 48.2 ± 0.08* |
| Med1fl/fl | 6 | F | 668 ± 17 | 11.3 ± 0.07 | 2.3 ± 0.19 | 43.5 ± 4.1 | 9.0 ± 0.7 | 5434 ± 638 | 79.0 ± 0.02 |
| Med1cKO | 7 | F | 481 ± 29** | 48.5 ± 15.8** | 32.6 ± 12.2** | 69.4 ± 6.6** | 16.0 ± 1.7** | 7823 ± 1202 | 44.8 ± 0.08** |
| Adult | |||||||||
| Med1fl/fl | 6 | M | 629 ± 47 | 32.0 ± 5.9 | 9.3 ± 2.9 | 76.2 ± 3.3 | 22.6 ± 3.4 | 13673 ± 1579 | 72 ± 0.03 |
| Med1cKO-MCM | 9 | M | 640 ± 46 | 86.5 ± 9.9* | 67.6 ± 10.4* | 102.9 ± 6.9* | 18.9 ± 2.8 | 12439 ± 2144 | 26 ± 0.06* |
| Med1fl/fl | 4 | F | 645 ± 47 | 41.0 ± 10.5 | 11.0 ± 3.2 | 88.5 ± 11.1 | 30.0 ± 7.4 | 9233 ± 3984 | 74 ± 0.02 |
| Med1cKO-MCM | 5 | F | 513 ± 78 | 106.9 ± 12.6** | 79.6 ± 14.7** | 122.4 ± 11.3** | 27.4 ± 2.8 | 13879 ± 2326 | 28 ± 0.06** |
Values are means ± SE. Echocardiographic analysis of 3-wk-old Med1fl/fl and Med1cKO male (M) and female (F) mice and Med1fl/fl and Med1cKO-MCM male and female mice 21–28 days after the start of tamoxifen treatment. HR, heart rate; EDV, end diastolic volume; ESV, end systolic volume; SV, stroke volume; CO, cardiac output; EF, ejection fraction.
*
P < 0.05 compared with Med1fl/fl M mice;
**
P < 0.05 compared with Med1fl/fl F mice.